Johnson & Johnson acquires Shockwave Medical, bolstering its presence in cardiovascular intervention. The move marks a strategic shift, with around $30 billion invested in MedTech over 18 months.
Shockwave Medical Inc (NASDAQ:SWAV) is in the spotlight today, after blue-chip pharmaceutical giant Johnson & Johnson (NYSE: JNJ) announced it would buy the company for $13.1 billion, boosting its portfolio of cardiovascular disease treatment devices.
Johnson & Johnson JNJ agreed on Friday to acquire Shockwave Medical Inc SWAV for $335 per share in cash, corresponding to an enterprise value of approximately…
Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory AnginaSANTA CLARA, Calif., April 08, 2024 (GLOBE NEWSWIRE) Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development and commercialization of transformational technologies for the treatment of cardiovascular disease, today announced that investigators presented six-month data from the full population of the REDUCER-I study, alongside interim long-term follow-up results
Six-Month Results from REDUCER-I Trial Add to Positive Evidence of the Coronary Sinus Reducer to Treat Refractory Angina SANTA CLARA, Calif., April 08, 2024 Shockwave Medical, Inc. , a pioneer.